Last reviewed 2026-04-20 · How we verify

BNT162b2 vaccine

Not specified

Vaxxinity's BNT162b2 vaccine holds a significant market position as one of the leading COVID-19 vaccines, despite having no clinical trials listed. Its competitive advantage is somewhat overshadowed by mRNA-1273 from Moderna, which elicits higher and more durable humoral responses, and PTX-COVID19-B, which shows comparable safety and non-inferior immunogenicity. A key risk is the lack of clinical trial data, which may affect regulatory and public confidence. The pipeline outlook remains uncertain due to the requirement for a PD-L1 companion diagnostic for several indications, which could limit its broader application.

At a glance

Mechanism of action

Unfortunately, the mechanism of action for the BNT162b2 vaccine is not provided. Typically, vaccines work by introducing a small, harmless piece of a virus or a protein from the virus to the body, which triggers an immune response. This immune response helps the body recognize and fight the virus if it enters the body in the future.

Approved indications

• Prevention of COVID-19 in individuals 12 years of age and older
• Prevention of COVID-19 in individuals 5 years of age and older
• Prevention of COVID-19 in individuals 6 months through 4 years of age

Common side effects

• Injection site pain
• Fatigue
• Headache
• Myalgia
• Chills
• Pyrexia
• Lymphadenopathy
• Pain
• Arthralgia
• Diarrhoea
• Pain in extremity
• Nausea

Drug interactions

• Warfarin
• Immunosuppressants
• Live vaccines
• Interferons
• Corticosteroids
• Thalidomide
• Azathioprine
• Cyclophosphamide
• Methotrexate
• Sirolimus

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BNT162b2 vaccine CI brief — competitive landscape report
• BNT162b2 vaccine updates RSS · CI watch RSS
• Vaxxinity, Inc. portfolio CI